Swiss National Bank reduced its position in shares of Illumina Inc. (NASDAQ:ILMN) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 407,445 shares of the life sciences company’s stock after selling 3,000 shares during the period. Swiss National Bank owned 0.28% of Illumina worth $74,016,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ILMN. Global X Management Co. LLC increased its stake in shares of Illumina by 1,400.0% in the third quarter. Global X Management Co. LLC now owns 600 shares of the life sciences company’s stock worth $109,000 after buying an additional 560 shares during the last quarter. Penserra Capital Management LLC boosted its position in shares of Illumina by 94.5% in the third quarter. Penserra Capital Management LLC now owns 708 shares of the life sciences company’s stock worth $128,000 after buying an additional 344 shares during the period. Physicians Financial Services Inc. boosted its position in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the period. Finally, Fuller & Thaler Asset Management Inc. bought a new position in shares of Illumina during the second quarter worth about $112,000. Hedge funds and other institutional investors own 92.98% of the company’s stock.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Shares of Illumina Inc. (NASDAQ:ILMN) opened at 136.18 on Tuesday. Illumina Inc. has a 52-week low of $127.10 and a 52-week high of $196.47. The company has a market cap of $20.00 billion, a P/E ratio of 45.70 and a beta of 1.24. The stock has a 50 day moving average of $139.08 and a 200 day moving average of $152.96.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.10. The firm had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. Illumina had a net margin of 18.72% and a return on equity of 23.76%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 EPS. On average, equities analysts anticipate that Illumina Inc. will post $3.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Illumina Inc. (ILMN) Position Reduced by Swiss National Bank” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/29/illumina-inc-ilmn-position-reduced-by-swiss-national-bank.html.

A number of research analysts have issued reports on ILMN shares. Vetr raised shares of Illumina from a “strong sell” rating to a “sell” rating and set a $155.68 target price for the company in a report on Monday, August 1st. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Argus increased their target price on shares of Illumina from $175.00 to $185.00 and gave the company a “buy” rating in a report on Monday, August 8th. CL King cut shares of Illumina from a “buy” rating to a “neutral” rating in a report on Monday, August 22nd. Finally, Citigroup Inc. increased their target price on shares of Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a report on Monday, September 12th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the stock. Illumina has an average rating of “Hold” and a consensus target price of $152.88.

In other news, EVP Marc Stapley sold 1,270 shares of the stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $172.87, for a total transaction of $219,544.90. Following the transaction, the executive vice president now owns 33,916 shares in the company, valued at approximately $5,863,058.92. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 300 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total transaction of $52,287.00. Following the transaction, the director now owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.